Tonix Pharmaceuticals (NASDAQ:TNXP) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report report published on Monday morning. The brokerage issued a sell rating on the stock.

Tonix Pharmaceuticals Stock Performance

Shares of Tonix Pharmaceuticals stock opened at $11.50 on Monday. The stock’s fifty day moving average is $29.24 and its two-hundred day moving average is $25.22. The company has a market capitalization of $21.51 million, a PE ratio of 0.00 and a beta of 2.07. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a 52 week low of $10.82 and a 52 week high of $1,248.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, beating the consensus estimate of ($203.00) by $180.00. The company had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts expect that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in shares of Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after purchasing an additional 1,855,907 shares during the last quarter. PFG Investments LLC acquired a new stake in Tonix Pharmaceuticals during the fourth quarter worth about $72,000. Finally, Commonwealth Equity Services LLC acquired a new stake in Tonix Pharmaceuticals during the fourth quarter worth about $40,000. 82.26% of the stock is currently owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.